Susan Paprcka
About Susan Paprcka
Susan Paprcka is a scientist known for her contributions to cancer research, particularly in the area of AXL receptor tyrosine kinase inhibitors. She has presented her findings at notable conferences and has demonstrated significant anti-tumor activity of these inhibitors.
Work at Arcus Biosciences
Susan Paprcka holds the title of Scientist at Arcus Biosciences. In this role, she engages in research focused on cancer therapeutics. Her work contributes to the development of innovative treatments aimed at improving patient outcomes in oncology.
Research Contributions
Paprcka has participated in significant research presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Her contributions to this conference highlight her involvement in cutting-edge cancer research and her commitment to advancing the field.
Involvement with the Society for Immunotherapy of Cancer
Susan Paprcka has contributed to the Society for Immunotherapy of Cancer (SITC) through her research on AXL receptor tyrosine kinase inhibitors. This involvement underscores her dedication to exploring novel therapeutic strategies in cancer treatment.
AXL Receptor Tyrosine Kinase Inhibitors Research
Paprcka has been involved in studies that demonstrate the significant anti-tumor activity of AXL inhibitors. Her research focuses on the development of potent and selective AXL receptor tyrosine kinase inhibitors, contributing to the understanding of their potential in cancer therapy.